echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Mandard grade is high: it does not mean that esophageal adenocarcinoma does not respond to chemotherapy

    Br J Cancer: Mandard grade is high: it does not mean that esophageal adenocarcinoma does not respond to chemotherapy

    • Last Update: 2021-03-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Neoadjuvant therapy has now become the standard of treatment for esophageal cancer.
    The good response of patients to neoadjuvant therapy is closely related to the improvement of survival rate.
    The Mandard tumor regression grading standard is the current measure of response to chemotherapy.

    Neoadjuvant therapy has now become the standard of treatment for esophageal cancer.
    The good response of patients to neoadjuvant therapy is closely related to the improvement of survival rate.
    Neoadjuvant therapy has now become the standard of treatment for esophageal cancer.
    The good response of patients to neoadjuvant therapy is closely related to the improvement of survival rate.

    A high Mandard grade means that esophageal adenocarcinoma does not respond to chemotherapy.
    However, some patients with higher grades still show a decrease in tumor volume and lymph node response.
    Therefore, the study aims to explore the survival status and disease recurrence patterns of these patients.

    The study aims to explore the survival status and disease recurrence patterns of these patients.
    The study aims to explore the survival status and disease recurrence patterns of these patients.

    Researchers used multivariate Cox regression analysis to assess the patient's time to death and recurrence, and analyze related clinicopathological factors.
    And through computed tomography technology to evaluate the volume change of the tumor.

    Kaplan-Meier survival curve analysis of each lymph node response group

    The study included a total of 555 patients.
    The results showed that the patients' median survival time was 55 months (Mandard grades 1-3) and 21 months (Mandard grades 4 and 5).
    In the Mandard grade 4 and 5 groups (332 patients), the researchers compared patients with complete lymph node response and patients with persistent lymphadenopathy.
    The results showed that the survival rate of patients (90 months vs.
    18 months), The recurrence rate (local area 14.
    75% vs.
    28.
    74%, systemic 24.
    59% vs.
    48.
    42%) and the positive rate of circumferential margins (22.
    95% vs.
    68.
    11%) were improved.
    Further studies have shown that complete lymph node response is an independent predictor of improvement in patient survival (hazard ratio 0.
    34).
    Patients with complete lymph node response had a greater reduction in tumor volume after chemotherapy, and there was no significant difference between different Mandard grades.

    Kaplan-Meier analysis of patients' relapse-free survival rate

    All in all, the results of the study show that in patients with poor Mandard grade, complete lymph node response can significantly improve patient outcomes.
    Therefore, a high Mandard grade does not mean that patients do not respond to chemotherapy, and patients with slowed lymph node metastasis can still benefit from adjuvant chemotherapy.

    In patients with poor Mandard grade, complete lymph node response can significantly improve the patient's outcome.
    In patients with poor Mandard grade, complete lymph node response can significantly improve the patient's outcome.


    Original source:


    Knight, WRC, Baker, CR, Griffin, N.


    et al.
    org/10.


    org/10.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.